A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Phase 2
180
about 2.4 years
18+
38 sites in AZ, CA, CO +11
What this study is about
Researchers are testing different treatments for moderately to severely active rheumatoid arthritis. The trial will evaluate the efficacy and safety of lutikizumab, ravagalimab, or a combination of both compared to placebo. Participants will attend regular visits during it at a hospital or clinic.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lutikizumab
- 2.Take Placebo
- 3.Take Ravagalimab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Primary: Number of Participants with Adverse Events (AEs)
Secondary: Change from Baseline in DAS28 (CRP), Percentage Of Participants Achieving CR per CDAI, Percentage Of Participants Achieving Clinical Remission (CR) per DAS28 (CRP), Percentage Of Participants Achieving Low Disease Activity (LDA) per Disease Activity Score-28 With C-Reactive Protein (DAS28-CRP)
Immune